

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/701,887	11/04/2003	Steffen Nock	020144-002110US	6724	
20350	7590 04/14/2006		EXAMINER		
	ID AND TOWNSEND ARCADERO CENTER	KIM, YUNSOO			
EIGHTH FL			ART UNIT	PAPER NUMBER	
SAN FRANC	CISCO, CA 94111-383	4	1644		

DATE MAILED: 04/14/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	n No.	Applicant(s)				
		10/701,88	NOCK ET AL.					
	Office Action Summary	Examiner		Art Unit				
		Yunsoo Ki		1644				
Period fo	The MAILING DATE of this communication or Reply	n appears on the	cover sheet with the	correspondence a	ddress			
WHI( - Exte after - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR R CHEVER IS LONGER, FROM THE MAILIN insions of time may be available under the provisions of 37 Ci SIX (6) MONTHS from the mailing date of this communicatio D period for reply is specified above, the maximum statutory p reply within the set or extended period for reply will, by reply received by the Office later than three months after the led patent term adjustment. See 37 CFR 1.704(b).	IG DATE OF TH FR 1.136(a). In no eve on. period will apply and will statute, cause the appl	IS COMMUNICATIO int, however, may a reply be ti I expire SIX (6) MONTHS fror ication to become ABANDON	N. mely filed n the mailing date of this of ED (35 U.S.C. § 133).				
Status								
1)	Responsive to communication(s) filed on 2	25 January 2000	5.					
·		This action is no	='					
3)	· <del>_</del>							
	closed in accordance with the practice und	der <i>Ex parte Qu</i>	ayle, 1935 C.D. 11, 4	53 O.G. 213.				
Disposit	ion of Claims							
4)⊠								
	4a) Of the above claim(s) is/are with	hdrawn from cor	nsideration.					
5)	Claim(s) is/are allowed.							
6)⊠	Claim(s) <u>25-27</u> is/are rejected.							
7)	Claim(s) is/are objected to							
8)	Claim(s) are subject to restriction a	and/or election re	equirement.					
Applicat	ion Papers							
9)[	The specification is objected to by the Exa	miner.						
,	The drawing(s) filed on is/are: a)		objected to by the	Examiner.				
, —	Applicant may not request that any objection to							
	Replacement drawing sheet(s) including the co	orrection is require	ed if the drawing(s) is ol	ojected to. See 37 C	FR 1.121(d).			
11)[	The oath or declaration is objected to by the	ne Examiner. No	te the attached Office	e Action or form P	TO-152.			
Priority (	under 35 U.S.C. § 119							
12)	Acknowledgment is made of a claim for for	reign priority und	ler 35 U.S.C. § 119(a	a)-(d) or (f).				
	a) ☐ All b) ☐ Some * c) ☐ None of:							
•	Certified copies of the priority documents have been received.      Certified copies of the priority documents have been received in Application No							
	3. Copies of the certified copies of the	priority docume	nts have been receiv	red in this National	Stage			
	application from the International Bu	ureau (PCT Rule	e 17.2(a)).					
* (	See the attached detailed Office action for a	a list of the certif	ied copies not receiv	ed.				
Attachmer	at(s)		•					
1) Notic	ce of References Cited (PTO-892)		4) Interview Summar					
	ce of Draftsperson's Patent Drawing Review (PTO-94) mation Disclosure Statement(s) (PTO-1449 or PTO/S		Paper No(s)/Mail E  5) Notice of Informal		O-152)			
· _	rnation Disclosure Statement(s) (P10-1449 of P10/Ser No(s)/Mail Date 11/4/03.	וטיוטיו	6) Other:		- ·/			

Application/Control Number: 10/701,887 Page 2

Art Unit: 1644

## **DETAILED ACTION**

1. Applicants' remarks mailed 1/25/06 have been acknowledged.

- 2. Claims 25-27 are pending.
- 3. Applicants' IDS filed on 11/4/03 is acknowledged. The reference AF has been considered.
- 4. Applicant is required to update US priority in the first line of the specification and update status of all pending applications.
- 5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

6. Claims 25-27 stand rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Pat. No. 5,099,005 (of record) in view of U.S. Pat. No. 4,281,061 (of record) for the reasons set forth in the office action mailed 7/22/06.

Applicants' arguments filed on 1/25/06 have been fully considered but they are not persuasive.

Page 3

Art Unit: 1644

Applicants traversed the rejection based on that none of the references teach the use of N-glycosidase, or O-glycosylase rather teach away from use of N-glycosidase or O-glycosylase and none of the references teaches the use of N-glycosidase or O-glycosylase.

As stated in the previous office action, neuraminidase is the species of the suggested glycosidase or combination as evidenced in the instant specification, p. 5 and p. 9. Furthermore, in view of Sigma neuraminidase product sheet and as evidenced by the definition of sialic acid provided by "Wikipedia", the neuraminidase hydrolyzes sialic acids (e.g. nine-carbon monosaccharide) from complex glycans (e.g. oligosaccharides) and glycoproteins (e.g. immunoglobulins). Due to lack of definition of sugar, it is interpreted to include any oligosaccharide, monosaccharide moiety (e.g. sialic acid).

In addition, as claims drafted, the starting antibody material encompasses "partially" deglycosylated antibody, the deglycosylated antibody treated by neuraminidase results partial or wholly deglycosylated antibody. Further, the specific cleavage site between a glucose and an amino acid are not claimed.

Thus, the claimed limitation is taught by the '005 patent and combination of teachings remains obvious.

From the teachings of references, it would have been obvious to one of ordinary skill in art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of the ordinary in the art at the time of invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

7. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

Art Unit: 1644

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

8. Claims 25-27 stand provisionally rejected under the judicially created doctrine of double patenting over claims 1-9 of U.S. Pat. No. 6,720,165 B (of record).

Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims encompass a method of making F(ab)<sub>2</sub> fragments from glycosylated antibody.

As Applicant has requested that this double patenting rejection be held in abeyance until patentable subject matter has been identified in the instant application, the double patenting rejection is maintained.

- 9. No claims are allowable.
- 10. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yunsoo Kim whose telephone number is 571-272-3176. The examiner can normally be reached on Monday thru Friday 8:30 - 5:00PM.

Application/Control Number: 10/701,887 Page 5

Art Unit: 1644

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Yunsoo Kim

Patent Examiner

Technology Center 1600

April 4, 2006

Patrick J. Nolan, Ph.D.

**Primary Examiner** 

Technology Center 1600